698 related articles for article (PubMed ID: 18258855)
1. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
2. PICOT: a multidomain scaffolding inhibitor of hypertrophic signal transduction.
Samarel AM
Circ Res; 2008 Mar; 102(6):625-7. PubMed ID: 18369159
[No Abstract] [Full Text] [Related]
3. PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility.
Jeong D; Cha H; Kim E; Kang M; Yang DK; Kim JM; Yoon PO; Oh JG; Bernecker OY; Sakata S; Le TT; Cui L; Lee YH; Kim DH; Woo SH; Liao R; Hajjar RJ; Park WJ
Circ Res; 2006 Aug; 99(3):307-14. PubMed ID: 16809552
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
5. The novel cardiac z-disc protein CEFIP regulates cardiomyocyte hypertrophy by modulating calcineurin signaling.
Dierck F; Kuhn C; Rohr C; Hille S; Braune J; Sossalla S; Molt S; van der Ven PFM; Fürst DO; Frey N
J Biol Chem; 2017 Sep; 292(37):15180-15191. PubMed ID: 28717008
[TBL] [Abstract][Full Text] [Related]
6. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
[TBL] [Abstract][Full Text] [Related]
7. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes.
MacDonnell SM; Weisser-Thomas J; Kubo H; Hanscome M; Liu Q; Jaleel N; Berretta R; Chen X; Brown JH; Sabri AK; Molkentin JD; Houser SR
Circ Res; 2009 Aug; 105(4):316-25. PubMed ID: 19608982
[TBL] [Abstract][Full Text] [Related]
8. PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility.
Cha H; Kim JM; Oh JG; Jeong MH; Park CS; Park J; Jeong HJ; Park BK; Lee YH; Jeong D; Yang DK; Bernecker OY; Kim DH; Hajjar RJ; Park WJ
J Mol Cell Cardiol; 2008 Dec; 45(6):796-803. PubMed ID: 18929570
[TBL] [Abstract][Full Text] [Related]
9. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
[TBL] [Abstract][Full Text] [Related]
10. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
Luo Y; Jiang N; May HI; Luo X; Ferdous A; Schiattarella GG; Chen G; Li Q; Li C; Rothermel BA; Jiang D; Lavandero S; Gillette TG; Hill JA
Circulation; 2021 Jul; 144(1):34-51. PubMed ID: 33821668
[TBL] [Abstract][Full Text] [Related]
11. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling.
Ni YG; Berenji K; Wang N; Oh M; Sachan N; Dey A; Cheng J; Lu G; Morris DJ; Castrillon DH; Gerard RD; Rothermel BA; Hill JA
Circulation; 2006 Sep; 114(11):1159-68. PubMed ID: 16952979
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
13. Tropisetron inhibits high glucose-induced calcineurin/NFAT hypertrophic pathway in H9c2 myocardial cells.
Asadi F; Razmi A; Dehpour AR; Shafiei M
J Pharm Pharmacol; 2016 Apr; 68(4):485-93. PubMed ID: 26945895
[TBL] [Abstract][Full Text] [Related]
14. Leptin-induced cardiomyocyte hypertrophy reveals both calcium-dependent and calcium-independent/RhoA-dependent calcineurin activation and NFAT nuclear translocation.
Rajapurohitam V; Izaddoustdar F; Martinez-Abundis E; Karmazyn M
Cell Signal; 2012 Dec; 24(12):2283-90. PubMed ID: 22917533
[TBL] [Abstract][Full Text] [Related]
15. Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades.
Dai H; Jia G; Liu X; Liu Z; Wang H
Environ Toxicol Pharmacol; 2014 Jul; 38(1):263-71. PubMed ID: 24975447
[TBL] [Abstract][Full Text] [Related]
16. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
[TBL] [Abstract][Full Text] [Related]
17. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
[TBL] [Abstract][Full Text] [Related]
18. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.
Facundo HT; Brainard RE; Watson LJ; Ngoh GA; Hamid T; Prabhu SD; Jones SP
Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H2122-30. PubMed ID: 22408028
[TBL] [Abstract][Full Text] [Related]
19. Direct interaction and reciprocal regulation between ASK1 and calcineurin-NFAT control cardiomyocyte death and growth.
Liu Q; Wilkins BJ; Lee YJ; Ichijo H; Molkentin JD
Mol Cell Biol; 2006 May; 26(10):3785-97. PubMed ID: 16648474
[TBL] [Abstract][Full Text] [Related]
20. Aspirin Attenuates Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting the Ca(2+)/Calcineurin-NFAT Signaling Pathway.
Yin Z; Wang X; Zhang L; Zhou H; Wei L; Dong X
Cardiovasc Ther; 2016 Feb; 34(1):21-9. PubMed ID: 26506219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
